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information for quality review and outcomes analyses as HCT
evolves. Databases must have speciﬁcity yet ﬂexibility in
customizing data elements. Purchased proprietary applica-
tions are used bymany HCT programs, but are limited by lack
of cost-efﬁcient conﬁgurability for center-speciﬁc needs. We
sought to develop an HCT research application allowing
evolution for program and scientiﬁc growth without major
developmental costs. We identiﬁed 5 features essential for
a functional HCT database including: 1) Uniform data
capture; 2) Center-speciﬁc adaptability; 3) Rapid report
generation; 4) Accurate, current data; and 5) Productivity
tracking.
Between August 2010 and March 2012, our team of IT
developers, programmer analysts, data managers, and
a HCT physician planned, developed, tested, and launched
a new database “BRAIN” (Blood and Marrow Transplant
Research Analysis and Information Network). This
required assessment of essential data, mapping and
migration of data from a legacy database, and interface
creation to available center systems. Legacy data was
reviewed, standardized, and imported to BRAIN. Elec-
tronic interfaces connect institutional systems including
lab results and medications via the Mofﬁtt data ware-
house to BRAIN. Additionally, discrete data such as
staging and disease prognostic factors entered by clini-
cians into the electronic medical record interface with
BRAIN reducing potential reporting errors or missing data
elements. These interfaces, along with manual abstraction,
enhance data for center speciﬁc analyses and electronic
submission to CIBMTR via AGNIS. A dashboard identifying
data manager speciﬁc CIBMTR forms due creates a proﬁ-
cient process of tracking forms. Thus, with the advance-
ment of interfaces within the application and the
mapping of this discrete data to the CIBMTR, productivity
and accuracy are enriched. To date, two forms are
submitted to the CIBMTR via AGNIS. Continuing efforts to
map AGNIS-ready forms and development of a simple
query tool will allow further growth and functionality
within the application.
BRAIN fulﬁlls a program need for cost efﬁciently, managing
evolving data, enhancing data consistency, minimizing labor
for data entry, making data easily assessable within the
institution, and ensures current and accurate data submis-
sion to outside regulatory reporting agencies.330
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Background: It is well known that female fertility is
impaired after allogeneic stem cell transplantation (SCT),
however, more female patients become long term survives,
and wish to have children of their own. Data regarding
pregnancies and child births are scarce. The aim of this
study was to determine the proportion of female patients
obtaining documented pregnancy and motherhood
following SCT.Methods: We obtained data regarding pregnancies and
child births in consecutive female transplant recipients
from our center. The patients were treated with SCT in the
period from 1976 to 2012. Data was obtained through the
national centralized access to the patients’ medical records
including specialist treatment. Patients less than 17 years
of age at the time of analysis were excluded. In total, 161
women were included in the analysis. The median age at
SCT was 17.2 years, and 31.4 years at analysis. Of the 161
women, 24 (15%) died in the observation period, the
surviving 138 women were observed median 12.3 years
(0.5-36).
Results: Of the 161 women, 20 (12.3%) had at least one
documented pregnancy (i.e. fertile). One of the 20 women
which experienced pregnancy is dead and never gave
birth. Thirteen (8%) woman obtained motherhood: 8 had
one child, 5 had two children. All children born were
healthy. Among the women with a pregnancy, 9/20 (45%)
had non-malignant hematological disease, and 11/20 (55%)
had malignant disease, among the non-fertile women the
numbers were 36/141 (25%) and 106/141 (75%), respec-
tively (P ¼ .66). Of the woman with motherhood, 7/13
(54%) had non-malignant disease, whereas 38/148 (26%) of
the remaining women had non-malignant disease (P ¼
0,029).
Total body irradiation (TBI) was given to 7 (54%) of the
women with completed delivery, at a dosage of 200 cGy in 2
and 850-1200 cGy in 5 patients.
The median age at HSCT was not different among fertile
and non-fertile women, 18.6 (2.3-33) years and 16.7 (0,2-
34,6) years respectively (P ¼ .91).
Among evaluable patients, chronic graft versus host
disease (GvHD) was documented in 4/18 (22%) of the fertile
women, and 43/116 (37%) of the non-fertile women, P ¼
0,22.
Conclusion: Not all women are infertile following alloge-
neic SCT, despite treatment with TBI chemotherapy and
chronic GvHD. However, only 8% obtained motherhood,
emphasizing the need for fertility conservation proce-
dures. The current study beneﬁts from centralized access
to patient information ensuring a high quality of accurate
and complete data.331
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The number of hematopoietic cell transplants (HCT) for
Medicare beneﬁciaries has dramatically increased, height-
ening the need to address Medicare coverage and reim-
bursement. Previous analysis of CMS claims data by ASBMT
and NMDP suggested variability by HCT programs (HCTP) in
coding and billing. Addressing these issues may be critical to
ensure ﬁnancial solvency for HCTP and continued HCT access
for Medicare beneﬁciaries.
